DUBLIN–(BUSINESS WIRE)–The “Cell Line Development Services Global Market – Forecast To 2030” report has been added to ResearchAndMarkets.com’s offering.
The cell line development service market is expected to grow at a double digit CAGR from 2022 to 2030 to reach $2,093.2 million by 2030.
Increasing trend of biologics outsourcing and increasing approval and demand for biologics and biosimilars are driving the market.
While, growing incidence rate of oncology, autoimmune disorders, infectious diseases & genetic disorders, growth in research activities related to the diseases and also recombinant cell lines for the production recombinant biopharmaceutical proteins and technological advancements in cell line engineering (gene editing tools) & cell line development technologies, screening technologies and process development are giving immense growth opportunities for the market.
However, tedious procedure involved in the development of stable cell lines and high risk of contamination are restraining the market. Furthermore, stringent and complex regulations and the high cost and technical requirement to adhere to accreditations such as GMP are posing threat to the industry.
Cell line development service global market is classified based on the expression system, cell line type, application and geography. Based on expression system, cell line development service global market is segmented into microbial, mammalian and others.
Among these, mammalian expression system is accounted for the highest revenue of in 2022 and is expected to grow at a double digit CAGR from 2022 to 2030 due to increasing approval of novel biologics drugs with mammalian expression system, ability to add human-like post-translational modifications to the complex protein therapeutics and launch of advanced mammalian expression system to improve biologics development.
Based on the cell line type, global cell line development service market is segmented into CHO, Mouse Myeloma (NS0; Sp2/0), Human Embryonic Kidney (HEK), Baby Hamster Kidney (BHK), Hybridoma, Human Embryonic Retina (PER.C6) and others. Among these, CHO cell line accounted for the highest revenue in 2022 and is expected to grow at an early teen CAGR from 2022 to 2030 due to increasing approval of biologics which are developed from CHO cell lines, development of advanced CHO cell line development platform by the CDMO and collaboration to offer CHO based CLD services.
Cell lines are essential for a wide range of applications including gene function studies, drug discovery assays, the production of biotherapeutics and diagnostics. Based on application, cell line development service global market is segmented into research, bioproduction and diagnostics.
Among these, bioproduction segment accounted for the highest revenue in 2022 and is expected to grow at a double digit CAGR from 2022 to 2030 due higher demand of biologics & biosimilars for therapeutics application and increasing collaboration between the companies for the development & production of biotherapeutics using cell line development platforms.
North America commanded the highest revenue in 2022. The market is expected to grow at a high single digit CAGR of from 2022 to 2030. Asia-Pacific region is expected to grow at a early teen CAGR during the forecasted period.
Most of the CDO or CDMO offering cell line development services to generate cell lines for bio production, research or diagnostic purposes. Companies are developing advanced platforms to generate high-performance, highly stable, production cell lines.
For instance, in October 2022, Aragen Life Sciences has launched its RapTr 2022 cell line development platform. RapTr2022 offers a 33% reduction in CLD timelines and delivers increased titres up to 6g/l. The RapTr CLD services include the proven CHO-DG44 and CHO-GS cell lines and proprietary vector combinations with an innovative clone selection process.
Newer technologies such as automated screening methods, advanced cell line engineering techniques, enhanced expression systems, improved process monitoring, and use of single use bioreactor & micro bioreactor for small scale bioproduction are further expected to provide this market with lucrative future growth opportunities.
Screening of high producing cell clone one of important step in cell line development. Automated screening is used for screening of a large number of clones to identify the small subset of high producing clones. Nanofluidic technologies offer a promising solution to further miniaturize cell culture processes.
One such technology platform has been developed by Berkeley Lights. CDMO are adopting advanced clone selection technologies (such as omics, optofluidics, and siRNA) to enhance their cell line development services offerings. Apart from optiofludics technologies, CDMO are adding advanced single cell sorting technologies to expand their offerings.
The ability of non-human mammalian expression systems to produce non-human post translational modifications like N-glycolylneuraminic acid (NGNA) and alpha1,3-galactose (a-gal) that can affect the stability, biologic activity, immunogenicity and clearance of the biologic products produced from them has led to a gradual shift of focus to the equally productive and more valuable niche human expression systems.
Company Profiles
- Boehringer Ingelheim International Gmbh
- Catalent Inc.
- Charles River Laboratories
- Emergent Biosolutions Inc.
- Eurofins Scientific S.E.
- Fujifilm Holdings Corporation (Fujiflm Diosynth Biotechnol0Gies)
- Genscript Biotech Corporation
- Jsr Corporation
- Lonza Group Ltd.
- Merck Kga
- Samsung Biologics Co. Ltd.
- Sartorius Group
- Thermofisher Scientific Inc.
- Wuxi Biologics
Key Topics Covered:
1 Executive Summary
2 Market Dynamics
2.1 Drivers and Opportunities
2.1.1 Increasing Trend of Outsourcing
2.1.2 Increasing Approvals and Demand for Biologics and Biosimilars
2.1.3 Increasing Incidence and Prevalence of Chronic, Communicable and Autoimmune Diseases
2.1.4 Advanced Technologies for Screening and Cell Line Engineering
2.2 Restraints and Threats
2.2.1 Tedious Procedures Associated with the Development of Stable Cell Lines
2.2.2 Risk of Contamination Associated with Cell Line Development
2.2.3 Compliance with Stringent Regulatory Guidelines
2.2.4 High Cost and Technical Requirements to Obtain Gmp Certifications
3 Cell Line Development
3.1 Cell Line Construction
3.2 Host Cell Line Engineering Expression System
3.3 Expression Vector and Host Cell Line Engineering
3.4 Transient Gene Expression
3.5 Stable Cell Line Development
3.6 Screening
3.7 Upstream Process Development
4 Host Cell Lines
5 Cell Line Development Global Market, Based on Region
6 Cell Line Development Services Market, Based on Expression System
6.1 Mammalian Expression Systems
6.2 Microbial Expression Systems
6.3 Others (Insect and Plant Cell)
7 Cell Line Development Services, Based on Cell Line Type
7.1 Cho
7.2 Murine/Mouse Myeloma (Ns0, Sp2/0)
7.3 Baby Hamster Kidney (Bhk) Cells
7.4 Human Embryonic Kidney (Hek) Cells
7.5 Human Embryonic Retinal Cells (Per.C6)
7.6 Hybridoma
7.7 Others (E.Coli, Yeast, Insect Cell, Vero Ht-1080, Hela, Cap, Hkb-11, Huh-7)
8 Cell Line Development Services, Based on Applications
8.1 Research
8.2 Bioproduction
8.3 Diagnostics
9 Cell Banking and Characterization Services
9.1 Cell Banking Services
9.2 Cell Line Characterization Services
10 Market Share Analysis
10.1 Key Developments
10.1.1 Agreement, Collaboration and Partnership
10.1.2 New Technology, Product and Service Launch
10.1.3 Expansion
10.1.4 Other Developments
11 Company Profiles
11.1 Overview
11.2 Financials
11.3 Service Portfolio
11.4 Key Developments
11.5 SWOT Analysis
Companies Mentioned
- 3P Biopharmaceuticals
- 53 biologics
- A & G Pharmaceutical Inc (Precision Antibody)
- Abzena PLC
- AGC Inc. (AGC Biologics)
- Anthem Biosciences Private Limited.
- Applied StemCell Inc.
- Aragen Bioscience
- Avid Bioservices Inc
- Biologics International Corp
- Bioneer A/S
- Biovian Oy
- Boehringer Ingelheim International GmbH
- BPS Bioscience, Inc.
- Canton Biologics Co., Ltd
- Catalent Inc.
- Celonic AG
- Charles River Laboratories International Inc.
- CJ Cheiljedang (Batavia Biosciences B.V)
- Creative Biolabs
- Curia
- EirGenix, Inc.
- Emergent Biosciences
- Eurofins Scientific S.E
- Evotec
- ExcellGene SA
- Fujifilm Holdings Corporation (Fujifilm Diosynth Biotechnologies)
- Fusion Antibodies
- Genscript Biotech Corporation
- Great Bay Bio
- GVK Biosciences Private Limited
- Hepalink (Cytovance Biologics & SPL)
- JSR Corporation [JSR Life Sciences, LLC (KBI biopharma, Selexis SA, CrownBio)]s
- Kemwell Biopharma
- LFB Biomanufacturing
- Lonza Group Ltd.
- Matica Biotechnology, Inc. (Matica Bio)
- Merck KGaA
- Minapharm Pharmaceuticals (Egypt)(ProBiogen AG)
- Mycenax
- Northway BiotechPharma
- Perkin Elmer
- Polpharma Biologics S.A
- Premas Biotech Pvt Ltd
- Rentschler Biopharma SE
- Samsung Biologics Co. Ltd.
- Sartious Group
- Sino Biological Inc
- Syd labs
- Syngene International Ltd.
- Thermofischer Scientific Inc.
- Trenzyme GmbH
- Wuxi Biologics Inc.
For more information about this report visit https://www.researchandmarkets.com/r/qg2q1d
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900